Cytosorbents (CTSO) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Cytosorbents (CTSO) is set to release its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($0.07) per share and revenue of $9.79 million.
• The company's recent earnings report showed a negative net margin of 41.77% and a negative return on equity of 105.04%, highlighting ongoing financial challenges.
• Goldman Sachs recently increased its stake in Cytosorbents by 149.2%, signaling potential institutional interest in the company.

Cytosorbents (NASDAQ:CTSO - Get Free Report) will likely be releasing its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Cytosorbents to post earnings of ($0.07) per share and revenue of $9.79 million for the quarter.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.01 million. Cytosorbents had a negative return on equity of 105.04% and a negative net margin of 41.77%. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Stock Up 4.8%

Shares of NASDAQ CTSO traded up $0.04 during mid-day trading on Monday, reaching $0.91. 218,309 shares of the company were exchanged, compared to its average volume of 195,028. The firm has a 50-day moving average of $1.04 and a 200 day moving average of $1.03. The company has a quick ratio of 2.30, a current ratio of 2.61 and a debt-to-equity ratio of 0.98. Cytosorbents has a 1 year low of $0.71 and a 1 year high of $1.61. The stock has a market cap of $57.04 million, a price-to-earnings ratio of -3.25 and a beta of 1.19.

Analysts Set New Price Targets

CTSO has been the subject of several research analyst reports. D. Boral Capital restated a "buy" rating and issued a $10.00 price objective on shares of Cytosorbents in a research note on Monday, July 21st. Wall Street Zen assumed coverage on Cytosorbents in a research note on Wednesday, May 21st. They issued a "hold" rating on the stock. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Thursday, May 15th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cytosorbents stock. Goldman Sachs Group Inc. lifted its position in Cytosorbents Corporation (NASDAQ:CTSO - Free Report) by 149.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 62,662 shares of the medical research company's stock after purchasing an additional 37,519 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.10% of Cytosorbents worth $63,000 at the end of the most recent quarter. Institutional investors own 32.87% of the company's stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.